PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23583730-3 2013 METHODS: The current study has examined the in vitro stability, biological activity and in vivo therapeutic applicability of a novel second generation mini-PEGylated form of (pGlu-Gln)-CCK-8, (pGlu-Gln)-CCK-8[mPEG]. Pyrrolidonecarboxylic Acid 175-179 cholecystokinin Mus musculus 185-188 29329158-4 2018 (pGlu-Gln)-CCK-8 and gastrin-17 stimulated insulin secretion from BRIN-BD11 and 1.1B4 beta-cells, associated with no effect on membrane potential or [Ca]i. Pyrrolidonecarboxylic Acid 1-5 cholecystokinin Mus musculus 11-14 29329158-6 2018 In agreement, (pGlu-Gln)-CCK-8 improved glucose disposal and glucose-induced insulin release in mice. Pyrrolidonecarboxylic Acid 15-19 cholecystokinin Mus musculus 25-28 29329158-7 2018 In addition, (pGlu-Gln)-CCK-8 evoked clear satiety effects. Pyrrolidonecarboxylic Acid 14-18 cholecystokinin Mus musculus 24-27 29329158-10 2018 (pGlu-Gln)-CCK-8 and gastrin-17 also augmented human and rodent beta-cell proliferation and offered protection against streptozotocin-induced beta-cell cytotoxicity. Pyrrolidonecarboxylic Acid 1-5 cholecystokinin Mus musculus 11-14 23583730-4 2013 RESULTS: (pGlu-Gln)-CCK-8[mPEG] was completely resistant to enzymatic degradation and in addition displayed similar insulinotropic (p<0.05 to p<0.001) and satiating effects (p<0.01 to p<0.001) as (pGlu-Gln)-CCK-8. Pyrrolidonecarboxylic Acid 10-14 cholecystokinin Mus musculus 20-23 23583730-5 2013 This confirmed the capability of (pGlu-Gln)-CCK-8[mPEG] to bind to and activate the CCK receptor. Pyrrolidonecarboxylic Acid 34-38 cholecystokinin Mus musculus 44-47 23583730-5 2013 This confirmed the capability of (pGlu-Gln)-CCK-8[mPEG] to bind to and activate the CCK receptor. Pyrrolidonecarboxylic Acid 34-38 cholecystokinin Mus musculus 84-87 23583730-6 2013 Sub-chronic twice daily injection of (pGlu-Gln)-CCK-8[mPEG] in high fat fed mice for 35days significantly decreased body weight gain (p<0.05), food intake (p<0.01 to p<0.001) and triacylglycerol deposition in liver (p<0.001) and muscle (p<0.001). Pyrrolidonecarboxylic Acid 38-42 cholecystokinin Mus musculus 48-51 23583730-7 2013 Furthermore, (pGlu-Gln)-CCK-8[mPEG] markedly improved intraperitoneal glucose tolerance (p<0.05) and insulin sensitivity (p<0.001). Pyrrolidonecarboxylic Acid 14-18 cholecystokinin Mus musculus 24-27 23583730-8 2013 Despite this therapeutic profile, once daily injection of (pGlu-Gln)-CCK-8[mPEG] in high fat fed mice for 33days, at the same dose, was not associated with alterations in food intake and body weight. Pyrrolidonecarboxylic Acid 59-63 cholecystokinin Mus musculus 69-72 23583730-10 2013 CONCLUSION: These studies emphasise the therapeutic potential of (pGlu-Gln)-CCK-8[mPEG] and similar molecules. Pyrrolidonecarboxylic Acid 66-70 cholecystokinin Mus musculus 76-79 23583730-11 2013 GENERAL SIGNIFICANCE: A more detailed analysis of the dose and administration schedule employed for (pGlu-Gln)-CCK-8[mPEG] could provide a novel and effective compound to treat obesity-diabetes. Pyrrolidonecarboxylic Acid 101-105 cholecystokinin Mus musculus 111-114 23315994-0 2013 Beneficial effects of (pGlu-Gln)-CCK-8 on energy intake and metabolism in high fat fed mice are associated with alterations of hypothalamic gene expression. Pyrrolidonecarboxylic Acid 23-27 cholecystokinin Mus musculus 33-36 23164696-3 2013 RESULTS: Twice-daily injections of (pGlu-Gln)-CCK-8 alone and in combination with (Pro(3))GIP[mPEG] in high-fat-fed mice for 34 days significantly decreased the energy intake throughout the entire study (P<0.05 to P<0.01). Pyrrolidonecarboxylic Acid 36-40 cholecystokinin Mus musculus 46-49 23164696-5 2013 Administration of (pGlu-Gln)-CCK-8, (Pro(3))GIP[mPEG] or a combination of both peptides significantly (P<0.01 to P<0.001) decreased the overall glycaemic excursion in response to both oral and intraperitoneal glucose challenge when compared with the controls. Pyrrolidonecarboxylic Acid 19-23 cholecystokinin Mus musculus 29-32 23164696-8 2013 In keeping with this, the estimated insulin sensitivity was restored to control levels by twice-daily treatment with (pGlu-Gln)-CCK-8, (Pro(3))GIP[mPEG] or a combination of both peptides. Pyrrolidonecarboxylic Acid 118-122 cholecystokinin Mus musculus 128-131 23388064-0 2013 Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice. Pyrrolidonecarboxylic Acid 84-88 cholecystokinin Mus musculus 94-97 23388064-3 2013 METHODS: This study has examined metabolic actions of exendin-4, GIP[mPEG] and a novel CCK-8 analogue, (pGlu-Gln)-CCK-8 as enzymatically stable forms of GLP-1, GIP and CCK, respectively. Pyrrolidonecarboxylic Acid 104-108 cholecystokinin Mus musculus 87-90 23388064-3 2013 METHODS: This study has examined metabolic actions of exendin-4, GIP[mPEG] and a novel CCK-8 analogue, (pGlu-Gln)-CCK-8 as enzymatically stable forms of GLP-1, GIP and CCK, respectively. Pyrrolidonecarboxylic Acid 104-108 cholecystokinin Mus musculus 114-117 23388064-3 2013 METHODS: This study has examined metabolic actions of exendin-4, GIP[mPEG] and a novel CCK-8 analogue, (pGlu-Gln)-CCK-8 as enzymatically stable forms of GLP-1, GIP and CCK, respectively. Pyrrolidonecarboxylic Acid 104-108 cholecystokinin Mus musculus 114-117 23388064-5 2013 Twice daily injection of (pGlu-Gln)-CCK-8 alone and in combination with exendin-4 or GIP[mPEG] in high fat-fed mice significantly decreased accumulated food intake (p < 0.05-p < 0.01), body weight gain (p < 0.05-p < 0.01) and improved (p < 0.05) insulin sensitivity in high fat-fed mice. Pyrrolidonecarboxylic Acid 26-30 cholecystokinin Mus musculus 36-39 23388064-7 2013 Combined treatment of (pGlu-Gln)-CCK-8 and exendin-4 resulted in significantly (p < 0.05) lowered circulating glucose levels and improved (p < 0.05) intraperitoneal glucose tolerance. Pyrrolidonecarboxylic Acid 23-27 cholecystokinin Mus musculus 33-36 23388064-9 2013 A single injection of (pGlu-Gln)-CCK-8, or combined with exendin-4, significantly (p < 0.05) lowered blood glucose levels 24 h post injection in untreated high fat-fed mice. Pyrrolidonecarboxylic Acid 23-27 cholecystokinin Mus musculus 33-36 23462797-2 2013 The present study assessed the biological effects of (pGlu-Gln)-CCK-8 and [D-Leu-4]-OB3, smaller isoforms of CCK and leptin, respectively. Pyrrolidonecarboxylic Acid 54-58 cholecystokinin Mus musculus 64-67 23462797-5 2013 In agreement, the acute dose-dependent glucose-lowering and insulinotropic actions of (pGlu-Gln)-CCK-8 were significantly enhanced by concurrent administration of [D-Leu-4]-OB3. Pyrrolidonecarboxylic Acid 87-91 cholecystokinin Mus musculus 97-100 23462797-8 2013 Combined treatment with (pGlu-Gln)-CCK-8 and [D-Leu-4]-OB3 resulted in significantly lowered plasma insulin levels, normalisation of circulating LDL-cholesterol and decreased triacylglycerol deposition in muscle. Pyrrolidonecarboxylic Acid 25-29 cholecystokinin Mus musculus 35-38 23462797-10 2013 There were no changes in overall locomotor activity or respiratory exchange ratio, but treatment with (pGlu-Gln)-CCK-8 significantly reduced (p < 0.001) energy expenditure. Pyrrolidonecarboxylic Acid 103-107 cholecystokinin Mus musculus 113-116 23462797-11 2013 CONCLUSIONS/INTERPRETATION: These studies highlight the potential of (pGlu-Gln)-CCK-8 alone and in combination with [D-Leu-4]-OB3 in the treatment of obesity and diabetes. Pyrrolidonecarboxylic Acid 70-74 cholecystokinin Mus musculus 80-83 23315994-2 2013 The present study examined the effects of twice daily administration of the N-terminally modified stable CCK-8 analogue, (pGlu-Gln)-CCK-8, on metabolic control and hypothalamic gene expression in high fat fed mice. Pyrrolidonecarboxylic Acid 122-126 cholecystokinin Mus musculus 105-108 23315994-2 2013 The present study examined the effects of twice daily administration of the N-terminally modified stable CCK-8 analogue, (pGlu-Gln)-CCK-8, on metabolic control and hypothalamic gene expression in high fat fed mice. Pyrrolidonecarboxylic Acid 122-126 cholecystokinin Mus musculus 132-135 23315994-4 2013 Furthermore, (pGlu-Gln)-CCK-8 markedly improved glucose tolerance (p<0.05) and insulin sensitivity (p<0.05). Pyrrolidonecarboxylic Acid 14-18 cholecystokinin Mus musculus 24-27 23315994-7 2013 These studies underscore the potential of (pGlu-Gln)-CCK-8 for the treatment of obesity-diabetes and suggest modulation of NPY and melanocortin related pathways may be involved in the observed beneficial effects. Pyrrolidonecarboxylic Acid 43-47 cholecystokinin Mus musculus 53-56 23055535-3 2013 Twice-daily injection of (pGlu-Gln)-CCK-8 for 28 days resulted in significantly lowered body weights (P<0.05) on days 24 and 28, which was associated with decreased accumulated calorie intake (P<0.01) from day 12 onward. Pyrrolidonecarboxylic Acid 26-30 cholecystokinin Mus musculus 36-39 23055535-6 2013 However, following a 15-min refeeding period in 18-h fasted mice, glucose levels were significantly (P<0.05) decreased by (pGlu-Gln)-CCK-8 despite similar food intake and nutrient-induced insulin levels. Pyrrolidonecarboxylic Acid 126-130 cholecystokinin Mus musculus 136-139 23055535-7 2013 Insulin sensitivity in (pGlu-Gln)-CCK-8-treated mice was significantly (P<0.01) improved compared with controls. Pyrrolidonecarboxylic Acid 24-28 cholecystokinin Mus musculus 34-37 22814764-3 2012 METHODS: The biological actions of (pGlu-Gln)-CCK-8 were comprehensively evaluated in pancreatic clonal BRIN BD11 cells and in vivo in high-fat-fed and ob/ob mice. Pyrrolidonecarboxylic Acid 36-40 cholecystokinin Mus musculus 46-49 22814764-4 2012 RESULTS: (pGlu-Gln)-CCK-8 was completely resistant to enzymatic degradation and its satiating effects were significantly (p < 0.05 to p < 0.001) more potent than CCK-8. Pyrrolidonecarboxylic Acid 10-14 cholecystokinin Mus musculus 20-23 22814764-4 2012 RESULTS: (pGlu-Gln)-CCK-8 was completely resistant to enzymatic degradation and its satiating effects were significantly (p < 0.05 to p < 0.001) more potent than CCK-8. Pyrrolidonecarboxylic Acid 10-14 cholecystokinin Mus musculus 168-171 22814764-5 2012 In BRIN-BD11 cells, (pGlu-Gln)-CCK-8 exhibited enhanced (p < 0.01 to p < 0.001) insulinotropic actions compared with CCK-8. Pyrrolidonecarboxylic Acid 21-25 cholecystokinin Mus musculus 31-34